Replies to post #1421 on MannKind Corp. (MNKD)

[primarywatcher]

I think it wise not to have all my ducks lined up with rose colored glasses, with over $45k invested on this stock. Soooo, I'm holding firm through the 1st week of August, but will take pause for the analysis on phase 3, type 1 and 2.

Details are very important. Just to confirm:

1. You wrote: "I also read an interview with someone who worked for the fda, says approval will happen." No doubt every poster on this board would like to read THAT interview! Where's link???

2. 85% FDA approval rate? I believe you're referencing this article:
http://www.benzinga.com/analyst-ratings/analyst-color/13/06/3696626/analyst-suggests-mannkind-could-receive-fda-approval-for#ixzz2X7uPRAar

The analyst believes MannKind's new drug Afrezza is ready for approval by the FDA -- with one catch: the drug needs to pass two trials with flying colors.

The trials may show some risk of hypoglycemia and other cardiovascular risks, but won't consider pulmonary inflammation or lung cancer, according to the Summer Street analyst. Summer Street highlighted a survey taker suggesting there is an 85 percent chance Afrezza in type 1 diabetes will meet endpoint benchmarks of non-inferiority to injectable insulin.

As I hold my position into August, I'm going to pay particular attention to ANY DETAILS regarding the afore mentioned:

The trials may show some risk of hypoglycemia and other cardiovascular risks, but won't consider pulmonary inflammation or lung cancer, according to the Summer Street analyst.

GLYA!